Latest news with #Russell3000HealthCareIndex
Yahoo
12-05-2025
- Business
- Yahoo
RadNet (RDNT) Fell on Lower Than Expected Guidance
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as RadNet, Inc. (NASDAQ:RDNT). Headquartered in Los Angeles, California, RadNet, Inc. (NASDAQ:RDNT) provides outpatient diagnostic imaging services. One-month return of RadNet, Inc. (NASDAQ:RDNT) was 4.36%, and its shares gained 0.04% of their value over the last 52 weeks. On May 9, 2025, RadNet, Inc. (NASDAQ:RDNT) stock closed at $55.74 per share with a market capitalization of $4.181 billion. Baron Health Care Fund stated the following regarding RadNet, Inc. (NASDAQ:RDNT) in its Q1 2025 investor letter: "Higher exposure to lagging life sciences tools & services stocks and poor stock selection in health care services and managed health care were other material detractors in the period. The Fund's only position in health care services, diagnostic imaging services provider RadNet, Inc. (NASDAQ:RDNT), weighed on performance after reporting below consensus guidance for fiscal year 2025. We view the reasons for the lower guidance as non-recurring and remain excited about the optionality embedded in RadNet's AI products, which provide enhanced digital image reading and analysis, boosting radiologists' accuracy and efficiency." A radiologist studying a monitor with a detailed image of a lung cancer tumor. RadNet, Inc. (NASDAQ:RDNT) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held RadNet, Inc. (NASDAQ:RDNT) at the end of the fourth quarter which was 20 in the previous quarter. In the fourth quarter, RadNet, Inc.'s (NASDAQ:RDNT) revenue increased 13.5% to $477.1 million and adjusted EBITDA increased 14% from Q4 2023 to $75 million. While we acknowledge the potential of RadNet, Inc. (NASDAQ:RDNT) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered RadNet, Inc. (NASDAQ:RDNT) and shared top performing stocks of the last 20 years listed by Jim Cramer. ClearBridge SMid Cap Strategy invested in RadNet, Inc. (NASDAQ:RDNT) during Q4 2024, recognizing its promising growth potential. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Here's Why Arcellx (ACLX) Declined in Q1
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Arcellx, Inc. (NASDAQ:ACLX). Headquartered in Redwood City, California, Arcellx, Inc. (NASDAQ:ACLX) engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The one-month return of Arcellx, Inc. (NASDAQ:ACLX) was -4.56%, and its shares gained 15.63% of their value over the last 52 weeks. On May 9, 2025, Arcellx, Inc. (NASDAQ:ACLX) stock closed at $57.55 per share with a market capitalization of $3.17 billion. Baron Health Care Fund stated the following regarding Arcellx, Inc. (NASDAQ:ACLX) in its Q1 2025 investor letter: "Arcellx, Inc. (NASDAQ:ACLX) is developing cell therapies for multiple myeloma, including lead drug anito-cel in partnership with Gilead. Shares detracted from performance. The stock had run up as investors anticipated positive news ahead of results released in early December from a pivotal iMMagine-1 trial. Despite encouraging data showing that anito-cel is as efficacious as Legend/ Johnson & Johnson's CARVYKTI with fewer side effects, shares then fell on fears of any new safety signals as Arcellx conducts additional trials. We think anito-cel is meaningfully differentiated on safety, and new data readouts will support this conclusion. We expect a mid-year update on trial results, which could be the basis for potential approval and launch in the second half of 2026." A scientist in a lab coat examining a microscope, looking at the details of the biotechnology company's immunotherapies. Arcellx, Inc. (NASDAQ:ACLX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held Arcellx, Inc. (NASDAQ:ACLX) at the end of the fourth quarter which was 32 in the previous quarter. While we acknowledge the potential of Arcellx, Inc. (NASDAQ:ACLX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Arcellx, Inc. (NASDAQ:ACLX) and shared takeover rumors that have prompted hedge funds to buy stocks. Baron healthcare fund initiated a position in Arcellx, Inc. (NASDAQ:ACLX) during Q2 2023, focusing on cell therapy's potential for multiple myeloma care. In Q1 2024, the fund increased its stake, but Arcellx, Inc. (NASDAQ:ACLX) dropped in Q2 2024 due to lack of news and competitor programs. However, Arcellx, Inc. (NASDAQ:ACLX) surged in Q3 2024, as its iMMagine-1 trial data for late-line multiple myeloma was confirmed for presentation at the American Society for Hematology conference later this year. In Q4 2024, the fund again increased its stake in Arcellx, Inc. (NASDAQ:ACLX), driven by its accelerated growth trajectory. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Here's Why Arcellx (ACLX) Declined in Q1
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Arcellx, Inc. (NASDAQ:ACLX). Headquartered in Redwood City, California, Arcellx, Inc. (NASDAQ:ACLX) engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The one-month return of Arcellx, Inc. (NASDAQ:ACLX) was -4.56%, and its shares gained 15.63% of their value over the last 52 weeks. On May 9, 2025, Arcellx, Inc. (NASDAQ:ACLX) stock closed at $57.55 per share with a market capitalization of $3.17 billion. Baron Health Care Fund stated the following regarding Arcellx, Inc. (NASDAQ:ACLX) in its Q1 2025 investor letter: "Arcellx, Inc. (NASDAQ:ACLX) is developing cell therapies for multiple myeloma, including lead drug anito-cel in partnership with Gilead. Shares detracted from performance. The stock had run up as investors anticipated positive news ahead of results released in early December from a pivotal iMMagine-1 trial. Despite encouraging data showing that anito-cel is as efficacious as Legend/ Johnson & Johnson's CARVYKTI with fewer side effects, shares then fell on fears of any new safety signals as Arcellx conducts additional trials. We think anito-cel is meaningfully differentiated on safety, and new data readouts will support this conclusion. We expect a mid-year update on trial results, which could be the basis for potential approval and launch in the second half of 2026." A scientist in a lab coat examining a microscope, looking at the details of the biotechnology company's immunotherapies. Arcellx, Inc. (NASDAQ:ACLX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 37 hedge fund portfolios held Arcellx, Inc. (NASDAQ:ACLX) at the end of the fourth quarter which was 32 in the previous quarter. While we acknowledge the potential of Arcellx, Inc. (NASDAQ:ACLX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Arcellx, Inc. (NASDAQ:ACLX) and shared takeover rumors that have prompted hedge funds to buy stocks. Baron healthcare fund initiated a position in Arcellx, Inc. (NASDAQ:ACLX) during Q2 2023, focusing on cell therapy's potential for multiple myeloma care. In Q1 2024, the fund increased its stake, but Arcellx, Inc. (NASDAQ:ACLX) dropped in Q2 2024 due to lack of news and competitor programs. However, Arcellx, Inc. (NASDAQ:ACLX) surged in Q3 2024, as its iMMagine-1 trial data for late-line multiple myeloma was confirmed for presentation at the American Society for Hematology conference later this year. In Q4 2024, the fund again increased its stake in Arcellx, Inc. (NASDAQ:ACLX), driven by its accelerated growth trajectory. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Here's Why Baron Health Care Fund Reacquired McKesson Corporation (MCK) in Q1
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as McKesson Corporation (NYSE:MCK). McKesson Corporation (NYSE:MCK) offers healthcare services through U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International segments. The one-month return of McKesson Corporation (NYSE:MCK) was 0.07%, and its shares gained 25.04% of their value over the last 52 weeks. On May 9, 2025, McKesson Corporation (NYSE:MCK) stock closed at $693.46 per share with a market capitalization of $86.683 billion. Baron Health Care Fund stated the following regarding McKesson Corporation (NYSE:MCK) in its Q1 2025 investor letter: "Minimally offsetting the above was strength in health care distributors attributable to a combination of stock selection and active exposure to this strong performing sub-industry. Recent addition McKesson Corporation (NYSE:MCK), a leading distributor of pharmaceutical/medical supplies and provider of prescription technology solutions that connect pharmacies, providers, payers, and biopharmaceutical customers, led the way in health care distributors. We discuss why we re-established a position in McKesson in the Recent Activity section below. A successful pharmacist in front of shelves of drugs in a community-based oncology pharmacy. McKesson Corporation (NYSE:MCK) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 78 hedge fund portfolios held McKesson Corporation (NYSE:MCK) at the end of the fourth quarter compared to 57 in the third quarter. While we acknowledge the potential of McKesson Corporation (NYSE:MCK) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered McKesson Corporation (NYSE:MCK) and shared the list of Jim Cramer recently discussed. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
12-05-2025
- Business
- Yahoo
Glaukos Corporation (GKOS) Fell as its iDose Results Fell Short of Expectations
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Glaukos Corporation (NYSE:GKOS). Glaukos Corporation (NYSE:GKOS) is an ophthalmic pharmaceutical and medical technology company. The one-month return of Glaukos Corporation (NYSE:GKOS) was -3.18%, and its shares lost 16.98% of their value over the last 52 weeks. On May 9, 2025, Glaukos Corporation (NYSE:GKOS) stock closed at $89.96 per share with a market capitalization of $5.14 billion. Baron Health Care Fund stated the following regarding Glaukos Corporation (NYSE:GKOS) in its Q1 2025 investor letter: "Glaukos Corporation (NYSE:GKOS) develops and sells interventional glaucoma treatments, including iDose, a minimally invasive drug-delivery device launched in 2024. An iDose is implanted as a five minute procedure and delivers highly concentrated prostaglandin inside the eye effective for up to three years. Shares declined on quarterly iDose results that missed elevated investor expectations. Although feedback has been positive, doctors have been hesitant to use iDose until they are confident they will receive reimbursement for this expensive device. Medicare coverage has started to solidify in some regions, and we think coverage across the board is a matter of when, not if. We believe uptake will accelerate over the coming quarters as the reimbursement process becomes more streamlined. Glaucoma is a large market that is ripe for new standalone interventions, and we think iDose can be a $1 billion product over time." A doctor examining a patient's eyes with an ophthalmic medical device. Glaukos Corporation (NYSE:GKOS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 30 hedge fund portfolios held Glaukos Corporation (NYSE:GKOS) at the end of the fourth quarter compared to 32 in the third quarter. In the first quarter of 2025, Glaukos Corporation's (NYSE:GKOS) reported revenue of $106.7 million representing 25% increase on a reported basis, or 26% on a constant currency basis compared to Q1 2024. While we acknowledge the potential of Glaukos Corporation (NYSE:GKOS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered Glaukos Corporation (NYSE:GKOS) and shared ClearBridge Small Cap Growth Strategy's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
